(Q41133458)

27 September 2017

Seizures during alpha interferon therapy (English)

1 reference

27 September 2017

Shakil AO

1

1 reference

PubMed ID

8834024

27 September 2017

Di Bisceglie AM

series ordinal

2

1 reference

PubMed ID

8834024

27 September 2017

Hoofnagle JH

series ordinal

3

1 reference

27 September 2017

1 January 1996

1 reference

27 September 2017

Journal of Hepatology

1 reference

27 September 2017

24

1 reference

27 September 2017

1

1 reference

27 September 2017

48-51

1 reference

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Neurological effects of recombinant human interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Psychiatric complications of long-term interferon alfa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Seizures associated with low-dose alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Interferon enhances the excitability of cultured neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

Interferon-associated retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980185-1

7 January 2021

10.1016/S0168-8278(96)80185-1

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8834024